Life Biosciences begins first human trial of cellular age-reversal therapy
ER-100 targets glaucoma patients using reprogramming factors that partially reset cells to a younger state
Life Biosciences administered the first dose of an experimental cellular reprogramming therapy to a human patient yesterday (June 9, 2026), marking a significant milestone in longevity science. This move represents the transition of age-reversal research from laboratory settings to actual human clinical trials. The U.S. FDA cleared the therapy for testing in January 2026.
From lab benches to human subjects
The therapy, known as ER-100, is being tested in a patient with glaucoma. Unlike standard anti-aging treatments that focus on slowing biological decline, this approach uses cellular reprogramming to partially restore cells to a more youthful state. The goal is to reset cellular function without the safety risks associated with turning mature cells entirely back into stem cells.
How the trial works
The study is a Phase 1 first-in-human safety and tolerability trial. Because it is the initial human phase, researchers are focused on safety metrics rather than immediate effectiveness. Key details of the trial design include:
- OCT4, SOX2, and KLF4 transcription factors (three of the original Yamanaka factors) are used as the primary reprogramming agents.
- The treatment is delivered via AAV delivery with doxycycline-inducible control, meaning doctors can turn the reprogramming on and off.
- The trial targets 18 participants across low- and high-dose cohorts.
- Administration involves an intravitreal injection (directly into the eye) followed by an 8-week activation period with doxycycline.
- Participants will be followed for up to 5 years to track long-term safety.
What this means for you
While this specific trial targets optic neuropathies like glaucoma (and later, a second cohort with non-arteritic anterior ischemic optic neuropathy), the success of cellular reprogramming could eventually be applied to a wide range of age-related conditions. It offers a potential path toward treating diseases affecting the brain, muscles, and vision through cellular repair rather than just managing symptoms with medications.
For now, the most important takeaway is the shift in methodology. We are moving into a phase where human safety data will dictate the future of age-reversal protocols. This is no longer theoretical: real patients are receiving the treatment, and the data collected will shape whether cellular reprogramming becomes a viable medical reality.
That progress alone gives you reason to be hopeful about the future of treating age-related disease. Instead of accepting declining vision, cognitive function, or muscle strength as inevitable, cellular reprogramming could one day let doctors repair the underlying biological clock that drives those changes.
This is informational content based on published research. It is not medical advice. Consult a healthcare professional before making changes to your health regimen.
Track the trial yourself
You can monitor the progress of the ER-100 trial via ClinicalTrials.gov (NCT07290244) to stay updated on the first human milestones of cellular reprogramming. The trial began enrolling participants on January 31, 2026.
